pharmaceuticals

The following post was written and/or published as a collaboration between Benzinga’s in-house sponsored content team and a financial partner of Benzinga. InMed Pharmaceuticals (NASDAQ: INM), a leader in the manufacturing and clinical development of rare cannabinoids, has released its...

Shortages of many generic drugs have plagued the U.S. health system for decades. The leading cause of drug shortages is quality issues at manufacturing plants, which are mostly overseas. Some experts argue that bringing pharmaceutical production back to the U.S. will help companies and regulators...

Investors who have owned stocks in the last year have generally experienced some big gains. In fact, the SPDR S&P 500 ETF Trust (NYSE: SPY) total return over the last 12 months is 33.6%. But there is no question some big-name stocks performed better than others along the way....

Citius Pharmaceuticals, Inc. (NASDAQ: CTXR) announced earlier this week an agreement with Dr. Reddy's Laboratories Ltd (NYSE: RDY) to acquire its exclusive license of E7777, a late-stage oncology immunotherapy for the treatment of cutaneous T-cell lymphoma, a rare form of non-Hodgkin...

BeyondSpring Inc’s (NASDAQ: BYSI) lead candidate plinabulin is likely to receive approval around the Nov. 30 PDUFA date for chemotherapy-induced neutropenia (CIN), according to Baird. The BeyondSpring Analyst: Joel Beatty initiated coverage of BeyondSpring with an Outperform rating and a...

The futures markets are pointing to a lower open on Wednesday, weighed down by European markets. The uncertainty around infrastructure, stimulus, and other government spending appears to be on investor’s minds.  Goldman Sachs (NYSE: GS) downgraded its economic outlook for the U.S....

Small-cap stocks have a history of outperforming large-cap names as they have the potential for rapid growth and have event-driven moves for share prices. A company focused on cancer screening and diagnostic tests has outperformed some of the largest healthcare companies over the last five...

The month of September marks a slow down in deal votes after recent months but still offers up several well-known companies that will go public if their SPAC merger votes are approved. SPAC merger votes can act as a catalyst as it completes the last step in the merger process and also changes...

The following post was written and/or published as a collaboration between Benzinga’s in-house sponsored content team and a financial partner of Benzinga. Lexaria has progressed significantly in evidencing that its patented DehydraTECH(TM) drug delivery technology can sufficiently improve...

Following the recent rally, Alkermes Plc’s (NASDAQ: ALKS) shares have exceeded their fair value and the stock looks “expensive on a relative basis,” according to BofA Securities. The Alkermes Analyst: Jason Gerberry downgraded the rating for Alkermes from Neutral to Underperform,...

Organon & Co (NYSE: OGN), which has recently spun-off from Merck & Co., Inc. (NYSE: MRK), has “inherited a global business across three segments,” namely Women’s Health, Legacy and Biosimilars brands, according to BofA Securities. The Organon Analyst: Jason Gerberry...

On this episode of Medically Necessary, Matt Blois welcomes Beth Schenk, executive director of environmental stewardship for the health system Providence. Blois and Schenk talk about the carbon footprint of the health care supply chain and how health care providers, distributors and manufacturers...

Praxis Precision Medicines Inc’s (NASDAQ: PRAX) lead asset has demonstrated encouraging data for central nervous system diseases and has a broad pipeline that targets both prevalent and rare disorders, according to BofA Securities. The Praxis Precision Medical Analyst: Tazeen Ahmad initiated...

Johnson & Johnson (NYSE: JNJ) announced recently a change in leadership with Alex Gorsky stepping down from his CEO role and handing the reigns to Joaquin Duato, who will take over on Jan. 3, 2022. Here are five things you might not know about Joaquin Duato, the next CEO of Johnson...

The following post was written and/or published as a collaboration between Benzinga’s in-house sponsored content team and a financial partner of Benzinga. Canadian clinical-stage drug development company InMed Pharmaceuticals is working to achieve pharmaceutical approval of rare...